- Home
- PSTX
as 12-20-2024 4:00pm EST
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 909.4M | IPO Year: | 2020 |
| Target Price: | $9.00 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.87 - $9.58 | Next Earning Date: | 11-07-2024 |
| Revenue: | $150,858,000 | Revenue Growth: | 203.18% |
| Revenue Growth (this year): | 131.92% | Revenue Growth (next year): | -70.55% |
Stock Insider Trading Activity of Poseida Therapeutics Inc. (PSTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gergen Mark J | PSTX | Executive Chairman | Dec 10 '24 | Sell | $9.46 | 30,000 | $283,866.00 | 651,291 | |
| Gergen Mark J | PSTX | Executive Chairman | Nov 26 '24 | Sell | $9.27 | 30,000 | $278,100.00 | 651,291 |
Latest Poseida Therapeutics Inc. News
PSTX Breaking Stock News: Dive into PSTX Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?
MT Newswires
11 days ago
Poseida Therapeutics Insider Sold Shares Worth $283,866, According to a Recent SEC Filing
MT Newswires
13 days ago
Poseida Therapeutics Says New Data Support Potential of Allogeneic Cell Therapy Platform
PR Newswire
13 days ago
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
Barrons.com
16 days ago
PBF Energy, Poseida Therapeutics, and More Stocks See Action From Activist Investors
MT Newswires
20 days ago
Piper Sandler Downgrades Poseida Therapeutics to Neutral, $10 Price Target
Zacks
20 days ago
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
Zacks
23 days ago
Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success
Compare PSTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PSTX Poseida Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.